Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 61 Туре R&D pipeline: Diabetes and obesity Product/project XultophyⓇ (NN9068)¹ Faster-acting insulin aspart (NN1218) Semaglutide (NN9535) OG217SC (NN9924) Semaglutide QD (NN9535) Anti-IL-21 and liraglutide (NN9828) LAI287 (NN1436) Mealtime insulin (NN1406) PYY diabetes (NN9748) Semaglutide QD (NN9536) G530S (NN9030) AM833 (NN9838) GG-co-agonist (NN9277) PYY obesity (NN9747) New formulation of insulin aspart Once-weekly GLP-1 analogue Immuno-metabolic combination of Anti-IL-21 and liraglutide Long-acting once-daily oral GLP-1 analogue Once-daily GLP-1 analogue Long-acting once-weekly basal insulin analogue Peptide YY analogue Liver-preferential mealtime insulin Once-daily GLP-1 analogue Glucagon analogue Long-acting amylin analogue Glucagon GLP-1 co-agonist Peptide YY analogue Indication Status (phase) 1 2 3 Filed Appr. Combination of insulin degludec and liraglutide Type 2 Type 1+2 Type 2 Type 2 Type 2 Type 1 Type 1+2 Type 1+2 Type 1+2 Obesity Obesity Obesity Obesity Obesity 1 Approved in EU on 18 Sep 2014 changing diabetes novo nordisk

View entire presentation